Abstract
Single autosomal trisomy is a common numerical cytogenetic abnormality in hematological malignancies, and shows a predilection for myeloid disorders. While the strong morphologic correlation as for chromosomal translocations is lacking, phenotypic associations are observed for the trisomies. Trisomy 10 is associated with aberrant CD7 expression in acute myeloid leukemia (AML), and trisomy 13 is associated with immature subtypes of AML having hand-mirror blast morphology. Cytogenetic abnormalities have been shown to be the most valuable prognostic determinant in AML and myelodysplastic syndrome (MDS). Trisomy 8, the commonest of the trisomies in myeloid disorders, is associated with an intermediate prognosis, while poor clinical outcome has been described in AML with trisomy 11 and trisomy 13. Additionally, the presence of a trisomy allows the application of fluorescence in situ hybridization (FISH) techniques in monitoring therapy response, detection of minimal residual disease and determination of l ineage involvement. The role of trisomy in pathogenesis remains to be defined and a gene dosage effect has been suspected. The recent finding of MLL gene duplication in association with trisomy 11 represents the first documented gene rearrangement in this setting. Finally, whether single autosomal trisomy is a primary or secondary cytogenetic abnormality is presently unclear. Evidence in favor of a secondary change includes frequent association with well-defined structural changes and translocations, and appearance of trisomy with disease evolution. In this respect, it is interesting to note that trisomy may be a cytogenetic marker for an underlying cryptic gene rearrangement, for example trisomy 22 and CBFbeeta MYH11 fusion in AML. This review will summarize the current understanding of single autosomal trisomy in myeloid disorders.
Keywords: Single Autosomal Trisomy, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Aberrant CD7 expression, Myeloid Leukemia AML, Fluorescence in situ hybridization, MLL Gene Duplication, Myeloid Disorders, Trisomy, Leukemogenesis
Current Genomics
Title: Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Volume: 1 Issue: 2
Author(s): S. K. Ma and T. S.K. Wan
Affiliation:
Keywords: Single Autosomal Trisomy, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Aberrant CD7 expression, Myeloid Leukemia AML, Fluorescence in situ hybridization, MLL Gene Duplication, Myeloid Disorders, Trisomy, Leukemogenesis
Abstract: Single autosomal trisomy is a common numerical cytogenetic abnormality in hematological malignancies, and shows a predilection for myeloid disorders. While the strong morphologic correlation as for chromosomal translocations is lacking, phenotypic associations are observed for the trisomies. Trisomy 10 is associated with aberrant CD7 expression in acute myeloid leukemia (AML), and trisomy 13 is associated with immature subtypes of AML having hand-mirror blast morphology. Cytogenetic abnormalities have been shown to be the most valuable prognostic determinant in AML and myelodysplastic syndrome (MDS). Trisomy 8, the commonest of the trisomies in myeloid disorders, is associated with an intermediate prognosis, while poor clinical outcome has been described in AML with trisomy 11 and trisomy 13. Additionally, the presence of a trisomy allows the application of fluorescence in situ hybridization (FISH) techniques in monitoring therapy response, detection of minimal residual disease and determination of l ineage involvement. The role of trisomy in pathogenesis remains to be defined and a gene dosage effect has been suspected. The recent finding of MLL gene duplication in association with trisomy 11 represents the first documented gene rearrangement in this setting. Finally, whether single autosomal trisomy is a primary or secondary cytogenetic abnormality is presently unclear. Evidence in favor of a secondary change includes frequent association with well-defined structural changes and translocations, and appearance of trisomy with disease evolution. In this respect, it is interesting to note that trisomy may be a cytogenetic marker for an underlying cryptic gene rearrangement, for example trisomy 22 and CBFbeeta MYH11 fusion in AML. This review will summarize the current understanding of single autosomal trisomy in myeloid disorders.
Export Options
About this article
Cite this article as:
Ma K. S. and Wan S.K. T., Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome, Current Genomics 2000; 1 (2) . https://dx.doi.org/10.2174/1389202003351553
DOI https://dx.doi.org/10.2174/1389202003351553 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Aging Liver: Can Exercise be a Better Way to Delay the Process than Nutritional and Pharmacological Intervention? Focus on Lipid Metabolism
Current Pharmaceutical Design Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data
Current Bioactive Compounds